Nido Biosciences announced plans to wind down operations in early 2026 after Phase II clinical data fell short of expectations. The Boston‑area company had been testing a candidate in oncology, and management cited the underwhelming efficacy readout as the primary driver for the decision to cease operations. The shutdown follows a wave of volatility for small biotech firms that encounter disappointing mid‑stage data without immediate alternate funding or partnering options. Nido’s closure highlights the financing fragility for clinical‑stage startups reliant on pivotal readouts to unlock additional capital or strategic deals. Stakeholders, including employees and investors, now await guidance on asset disposition and whether any programs will be out‑licensed or sold to preserve remaining value.